Fiera Capital Corp Has $30.65 Million Stock Position in Boston Scientific Corporation $BSX

Fiera Capital Corp grew its stake in Boston Scientific Corporation (NYSE:BSX) by 46.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 321,483 shares of the medical equipment provider’s stock after buying an additional 102,193 shares during the period. Fiera Capital Corp’s holdings in Boston Scientific were worth $30,653,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in BSX. Murphy & Mullick Capital Management Corp lifted its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $26,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the period. Bangor Savings Bank lifted its stake in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Finally, Board of the Pension Protection Fund acquired a new position in shares of Boston Scientific in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 9,800 shares of company stock worth $554,012 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. BTIG Research dropped their price objective on Boston Scientific from $80.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, June 2nd. Citigroup dropped their price objective on Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, May 28th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Barclays dropped their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Finally, Stifel Nicolaus set a $75.00 price objective on Boston Scientific in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $85.92.

Boston Scientific Price Performance

BSX stock opened at $48.73 on Tuesday. The stock has a market cap of $72.42 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The stock has a 50-day moving average price of $57.68 and a two-hundred day moving average price of $76.17. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1 year low of $47.17 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.